Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor for elderly patients with previously untreated acute myeloid leukemia

Leukemia Research

Volumn 34, Issue 5, 2010, Pages 610-614

  Suzushima, Hitoshi ^a   Wada, Naoko ^b   Yamasaki, Hiroshi ^c   Eto, Kenichiro ^d   Shimomura, Taizo ^a   Kugimiya, Michiko H ^a   Horikawa, Kentaro ^b   Nishimura, Shintaro ^d   Tsuda, Hiroyuki ^c   Mitsuya, Hiroaki ^b   Asou, Norio ^b  

^a NTT West Kyushu Hospital   (Japan)

^b KUMAMOTO UNIV SCHOOL OF MEDICINE   (Japan)

^c KUMAMOTO CITY HOSPITAL   (Japan)

^d Yatsushiro General Hospital   (Japan)

Author keywords

Aclarubicin; CAG; Cytarabine; Elderly acute myeloid leukemia; Granulocyte colony stimulating factor; Low dose chemotherapy

Indexed keywords

ACLARUBICIN; CYTARABINE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; KARYOTYPE; LEUKOCYTE COUNT; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPHIL COUNT; OVERALL SURVIVAL; PRIORITY JOURNAL; TREATMENT RESPONSE;

ACLARUBICIN; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTARABINE; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; KAPLAN-MEIERS ESTIMATE; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED;

EID: 77950076360     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2009.08.010     Document Type: Article

References (26)

1. Lowenberg B., Downing J.R., Burnett A. Acute myeloid leukemia. New Engl J Med 1999, 341:1051-1062.
2. Kolitz J.E. Current therapeutic strategies for acute myeloid leukaemia. Br J Haematol 2006, 134:555-572.
3. Appelbaum F.R., Gundacker H., Head D.R., Slovak M.L., Willman C.L., Godwin J.E., et al. Age and acute myeloid leukemia. Blood 2006, 107:3481-3485.
4. Rowe J.M. Treatment of acute mylogenous leukemia in older adults. Leukemia 2000, 14:480-487.
5. Estey E.H. How I treat older patients with AML. Blood 2000, 96:1670-1673.
6. Frohling S., Schlenk R.F., Kayser S., Morhardt M., Benner A., Dohner K., et al. Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B. Blood 2006, 108:3280-3288.
7. Farag S.S., Archer K.J., Mrozek K., Ruppert A.S., Caroll A.J., Vardiman J.W., et al. Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. Blood 2006, 108:63-73.
8. Saito K., Nakamura Y., Aoyagi M., Waga K., Yamamoto K., Aoyagi A., et al. Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) for previously treated mylogenous leukemia (AML) and previously untreated elderly patients with AML, secondary AML, and refractory anemia with excess blasts in transformation. Int J Hematol 2000, 71:238-244.
9. Qian S.X., Li J.W., Tian T., Shen Y.F., Jiang Y.Q., Lu H., et al. Effect of low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor priming (CAG regimen) in the outcome of elderly patients with acute myeloid leukemia. Leuk Res 2007, 31:1383-1388.
10. Grimwade D., Walker H., Harrison G., Oliver F., Chatters S., Harrison C.J., et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML 11 trial. Blood 2001, 98:1312-1320.
11. Clavio M., Vignolo L., Albarello A., Varaldo R., Pierri I., Catania G., et al. Adding low-dose gemtuzumab ozogamicin to fludarabine, Ara-C and idarubicin (MY-FLAI) may improve disease-free and overall survival in elderly patients with non-M3 acute myeloid leukaemia: results of a prospective, pilot, multi-centre trial and comparison with a historical cohort of patients. Br J Haematol 2007, 138:186-195.
12. Faderl S., Ravandi F., Huang X., Garcia-Manero G., Ferrajoli A., Estrov Z., et al. A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front line therapy for patient aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood 2008, 112:1638-1645.
13. Lowenberg B., Suciu S., Archimbaud E., Haak H., Stryckmans P., de Cataldo R., et al. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy. The value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia cooperative group of the European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group. Randomized phase III study AML-9. J Clin Oncol 1998, 16:872-881.
14. Anderson J.E., Kopecky K.J., Willman C.L., Head D., O'Donnell M., Luthardt F.W., et al. Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study. Blood 2002, 100:3869-3876.
15. Rowe J.M., Neuberg D., Friedenberg W., Bennett J.M., Paietta E., Makary A.Z., et al. A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. Blood 2004, 103:479-485.
16. van der Holt B., Lowenberg B., Burnett A.K., Knauf W.U., Shepherd J., Piccaluga P.P., et al. The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis. Blood 2005, 106:2646-2654.
17. Kantarjian H., O'Brien S., Cortes J., Giles F., Faderl S., Jabbour E., et al. Results of intensive chemotherapy in 998 patients aged 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome. Cancer 2006, 106:1090-1098.
18. Menzin J., Lang K., Earle C., Kerney D., Mallick R. The outcome and costs of acute myeloid leukemia among the elderly. Arch Intern Med 2002, 162:1597-1603.
19. Ishikura H., Sawada H., Okazaki T., Mochizuki T., Izumi Y., Yamagishi M., et al. The effect of low dose Ara-C in acute nonlymphoblastic leukaemias and atypical leukaemia. Br J Haematol 1984, 58:9-18.
20. Tilly H., Castaigne S., Bordessoule D., Sigaux F., Daniel M.T., Monconduit M., et al. Low-dose cytosine arabinoside treatment for acute nonlymphocytic leukemia in elderly patients. Cancer 1985, 55:1633-1636.
21. Powell B.L., Capizzi R.L., Muss H.B., Bearden J.D., Lyerly E.S., Rosenbaum D.L., et al. Low-dose Ara C therapy for acute myelogenous leukemia in elderly patients. Leukemia 1989, 3:23-28.
22. Tatetsu H., Matsuno F., Takatsu N., Miyake H., Hoshino K., Nosaka K., et al. Treatment of therapy-related acute myeloid leukemia occurring in elderly non-Hodgkin lymphoma patients with low-dose cytarabine, aclarubicin and granulocyte colony-stimulating factor. Leuk Res 2009, 33:197-200.
23. Büchner T., Hiddemann W., Berdel W.E., Wörmann W., Schoch C., Fonatsch, et al. 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group. J Clin Oncol 2003, 21:4496-4504.
24. Gardin C., Turlure P., Fagot T., Thomas X., Terre C., Contentin N., et al. Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial. Blood 2007, 109:5129-5135.
25. Lancet J.E., Gojo I., Gotlib J., Feldman E.J., Greer J., Liesveld J.L., et al. A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia. Blood 2007, 109:1387-1394.
26. Garcia-Manero G., Kantarjian H.M., Sanchez-Gonzalez B., Yang H., Rosner G., Verstovsek S., et al. Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemia. Blood 2006, 108:3271-3279.